Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590940 | 0.91 | TSHR (0.69) | SMN1; SMN2POLBALDH1A1NOTUMGAA | |
| SCHEMBL1545217 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL21515338 | 0.81 | CHRM2 (0.74) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL342522 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL30253474 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL25391399 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL14202790 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL3089154 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL29520673 | 0.80 | NOTUM (0.69) | SMN1; SMN2POLBALDH1A1KDM4EPKM | |
| SCHEMBL3660180 | 0.80 | NOTUM (0.69) | SMN1; SMN2POLBALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| US-20100280024-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| EP-2205559-A1 | RENIN INHIBITORS | Cadila Healthcare Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009087649-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | SMN1; SMN2 3745/4885POLB 4043/4885ALDH1A1 67/4885 |
| US-20100280024-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | SMN1; SMN2 4332/4885POLB 3063/4885ALDH1A1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.